Pro Medicus has secured a seven-year, A$25 million contract with Valley Health in the US. The deal covers its full range of Visage 7 imaging products, with the system expected to go live in early 2027.
HEALTHCARE & FITNESS
MS Patients Avoid $33,000 Treatment Costs Under PBS Deal
The government has confirmed that major multiple sclerosis medicines will remain on the PBS, providing financial relief for thousands of Australians.
Popular Reads
Category . Author
Story
Rick Rostolis to Step Down as Regis Healthcare CFO
The veteran finance executive will retire after overseeing the company's financial strategy, capital management and mergers and acquisitions activities.
Vertex Expands Rare Disease Portfolio With $10B Crinetics Buyout
The deal adds Crinetics' endocrine disease therapies to Vertex's pipeline and is expected to become accretive to adjusted operating income by 2029.
EchoIQ Lands $110 Million Backing for US Expansion of AI Cardiac Platform
The institutional placement will fund the growth of EchoIQ’s AI-enabled cardiovascular diagnostics business, building on its recent strategic partnership with Pro Medicus.
EU Panel Recommends Approval of Neuren’s Daybue
Neuren Pharmaceuticals has moved closer to European approval for its Rett syndrome treatment Daybue after receiving a positive recommendation from the EU's medicines regulator, paving the way for potential milestone payments and broader market access.
More healthcare & fitness News
01
Gina Rinehart Backs Cancer Imaging Startup With $72 Mn Investment
Hancock Prospecting has invested $72 million in US-based Lumitron Technologies to support the commercialisation of advanced imaging technology designed to improve cancer detection and identify contaminants in mining operations.
02
4D Medical Shares Fall Despite Winning Australian TGA Approval
4D Medical received Australian TGA approval for its CT:VQ lung imaging software, enabling immediate commercialisation. Despite the milestone, shares dropped 10.7% as the company also confirmed plans to seek Medicare reimbursement.
03
Ex-Organon Executive Meghan Rivera Joins Mayne Pharma Board
Mayne Pharma has appointed healthcare executive Meghan Rivera to its board, bringing experience from Organon, Akili Interactive and ViiV Healthcare.